Table 3.
Percentage change after 12 weeks on treatment of the circulating tumor cells (CTC) counts, prostate specific antigen (PSA) and the parameters derived from the whole body diffusion weighted imaging (WB-DWI) analysis with the different delineation techniques in responders and non-responders patients.
| % change after 12 weeks | Responders | Non-responders | Mann-Whitney p-value | ||||
|---|---|---|---|---|---|---|---|
| N | Median (Q1, Q3) |
Min, max | N | Median (Q1, Q3) |
Min, max | ||
| Clinical characteristics | |||||||
| CTC (number/7.5ml) |
6 | -96.0 (-100, -82.9) |
-100, -60.5 | 15 | -2.9 (-37.5, 75.0) |
-73.8, 312.5 | NA* |
| PSA (ng/ml) | 6 | -68.6 (-80.1, -37.5) |
-94.6, -29.3 | 15 | 89.9 (36.0, 239.0) |
-14.4, 525.6 | NA* |
| Axial skeleton DWI signal abnormality | |||||||
| Volume (L) | 6 | -41.1 (-52.9, -28.7) |
-58.8, -6.3 | 15 | 20.7 (3.2, 53.0) |
0.0, 76.9 | 0.001 |
| Median ADC (x10-6 mm2/s) |
6 | 35.4 (3.8, 44.1) |
1.3, 59.5 | 15 | 7.5 (3.7, 15.6) |
-9.0, 32.7 | 0.139 |
| Up to 5 target lesions | |||||||
| Volume (L) | 6 | -25.5 (-57.0, -18.2) |
-78.7, 4.54 | 15 | 14.6 (0.0, 47.5) |
-20.2, 76.9 | 0.002 |
| Median ADC (x10-6 mm2/s) |
6 | 26.3 (11.4, 47.4) |
4.8, 102.9 | 15 | 7.4 (-2.3, 12.9) |
-10.8, 25.6 | 0.024 |
| Central slice 5 target lesions | |||||||
| Diameter (mm) | 2 | -59.2 (-88.3, -30.1) |
-88.3, -30.1 | 7 | 3.8 (1.6, 41.4) |
0.0, 69.9 | 0.040 |
| Median ADC (x10-6 mm2/s) |
6 | 27.4 (14.0, 47.0) |
12.8, 52.3 | 15 | 10.0 (3.2, 17.2) |
-12.7, 63.1 | 0.018 |
| Entire axial skeleton | |||||||
| Median ADC (x10-6 mm2/s) |
6 | 7.4 (-0.8, 26.0) |
-16.6, 29.0 | 15 | 5.6 (3.4, 12.5) |
-21.6, 16.7 | 0.876 |
*
Changes in CTC and PSA were used to define response/non-response therefore formal comparisons have not been made.